Jl. Selam et al., SYMPTOMS, HORMONES, AND GLUCOSE FLUXES DURING A GRADUAL HYPOGLYCEMIA-INDUCED BY INTRAPERITONEAL VS VENOUS INSULIN INFUSION IN TYPE-I DIABETES, Diabetic medicine, 12(12), 1995, pp. 1102-1109
Citations number
NO
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
Intraperitoneal (IP) insulin infusion with programmable implantable pu
mps is associated with a reduction in hypoglycaemic events when compar
ed to intensive diabetes management with subcutaneous insulin in patie
nts with Type 1 diabetes mellitus. The mechanism may involve more phys
iological insulin kinetics, lower peripheral insulin levels or a speci
fic hepatic action of portal insulin on hypoglycaemic counter regulati
on. To investigate the latter two hypotheses, we performed two hypogly
caemic clamps (controlled blood glucose decrement to 2.2 mmol I-1) in
random order in 12 Type 1 diabetic patients. Insulin was infused eithe
r IP or IV for 150 min, at rates chosen to generate similar peripheral
insulin levels (1 mU/kg(-1) min(-1) IV or 2 mU/k(-1) min(-1) IP, n =
6) to evaluate direct hepatic action, or at similar rates (1 mU/kg(-1)
min(-1) IV and IP, n = 6) to evaluate IP indirect effects via lower p
eripheral insulinaemia. Hepatic glucose production and glucose utiliza
tion were measured by [6,6 H-2] glucose dilution technique. Glucose pr
oduction was lower (1.7 +/- 0.4 vs 0.5 +/- 0.4 mg kg(-1) min(-1), p <
0.05), and utilization was similar at the end of the matched-insulinae
mia IV and IP clamps, respectively. By contrast, glucose production wa
s higher (1.7 +/- 0.5 IV vs 2.7 +/- 0.3 IP mg kg(-1) min(-1), p < 0.01
) and glucose utilization lower (4.4 +/- 1.0 IV vs 3.3 +/- 0.2 IP mg k
g(-1) min(-1), p < 0.05) with IP delivery at the end of the matched-do
se clamps. Counterregulatory hormones and hypoglycaemic symptoms incre
ased similarly in all clamps. In summary, IP insulin, when compared to
IV insulin at similar delivery rates, but not at similar insulinaemia
, is associated with a less negative glucose balance (glucose producti
on-glucose utilization) during hypoglycaemia. Such a mechanism may pla
y a role in the reduced hypoglycaemic risk seen with IP implantable pu
mps.